Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
FR0012333284
Wed, 30.09.2020
ABIVAX
Abivax announces the release of its 2020 half-year financial report
PARIS, France, September 30, 2020 - 06:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces the publicati [ … ]
Thu, 24.09.2020
ABIVAX
Abivax presents first-half 2020 financial results and operations update
ABX464 Phase 2a ulcerative colitis two-year maintenance study results confirm good safety profile and durable efficacy of 50 mg once-daily oral ABX464
77% (180/232) of patients randomized in ABX464 Phase 2b ulcerative colitis study, recruitment expected to be completed by the [ … ]
Wed, 02.09.2020
ABIVAX
Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2a maintenance study
Phase 2a open label maintenance results after second year of treatment confirm good safety profile and durable efficacy of 50mg once-daily oral ABX464
After the second year of continued treatment, 69% of patients were in clinic [ … ]